These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation. Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045 [TBL] [Abstract][Full Text] [Related]
3. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma. Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933 [TBL] [Abstract][Full Text] [Related]
4. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069 [TBL] [Abstract][Full Text] [Related]
5. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma. Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425 [TBL] [Abstract][Full Text] [Related]
6. [Frequency and prognostic value of chromosome abnormalities in multiple myeloma]. Kurahashi S; Sawamoto A; Sugimoto T; Narimatsu H; Iwasaki T; Adachi T; Suzuki H; Hayakawa F; Sugiura I Rinsho Ketsueki; 2007 Nov; 48(11):1455-61. PubMed ID: 18080502 [TBL] [Abstract][Full Text] [Related]
7. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647 [TBL] [Abstract][Full Text] [Related]
9. An incremental response to high-dose therapy in multiple myeloma. Hawkins T; Horvath N; Rawling C; Bayly J; Andary C; Dyson P; Ho J; Dart G; Juttner C; To B Bone Marrow Transplant; 1996 Jun; 17(6):929-35. PubMed ID: 8807096 [TBL] [Abstract][Full Text] [Related]
10. Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP). Eom HS; Kim YK; Chung JS; Kim K; Kim HJ; Kim HY; Jin JY; Do YR; Oh SJ; Suh C; Seong CM; Kim CS; Lee DS; Lee JH Ann Hematol; 2010 May; 89(5):489-97. PubMed ID: 20012045 [TBL] [Abstract][Full Text] [Related]
11. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH; Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634 [TBL] [Abstract][Full Text] [Related]
12. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Qazilbash MH; Saliba RM; Ahmed B; Parikh G; Mendoza F; Ashraf N; Hosing C; Flosser T; Weber DM; Wang M; Couriel DR; Popat U; Kebriaei P; Alousi AM; Anderlini P; Naeem RC; Champlin RE; Giralt SA Biol Blood Marrow Transplant; 2007 Sep; 13(9):1066-72. PubMed ID: 17697969 [TBL] [Abstract][Full Text] [Related]
13. Transplantation as salvage therapy for high-risk patients with myeloma in relapse. Lee CK; Barlogie B; Zangari M; Fassas A; Anaissie E; Morris C; Van Rhee F; Cottler-Fox M; Thertulien R; Muwalla F; Mazher S; Badros A; Tricot G Bone Marrow Transplant; 2002 Dec; 30(12):873-8. PubMed ID: 12476279 [TBL] [Abstract][Full Text] [Related]
14. Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient. Yuan J; Shah R; Kulharya A; Ustun C Leuk Res; 2010 Jul; 34(7):954-7. PubMed ID: 20138360 [TBL] [Abstract][Full Text] [Related]
15. Clinical impact of chromosomal aberrations in multiple myeloma. Nahi H; Sutlu T; Jansson M; Alici E; Gahrton G J Intern Med; 2011 Feb; 269(2):137-47. PubMed ID: 21158983 [TBL] [Abstract][Full Text] [Related]
16. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. Harousseau JL; Avet-Loiseau H; Attal M; Charbonnel C; Garban F; Hulin C; Michallet M; Facon T; Garderet L; Marit G; Ketterer N; Lamy T; Voillat L; Guilhot F; Doyen C; Mathiot C; Moreau P J Clin Oncol; 2009 Dec; 27(34):5720-6. PubMed ID: 19826130 [TBL] [Abstract][Full Text] [Related]